Tags Archive Navigation
icon
-
Media ReleaseAveXis Statement on Changes to Senior Leadership Team
-
Media ReleaseAveXis Community Statement on Global Managed Access Program for AVXS-101
-
Media ReleaseAveXis Community Statement on the Coronavirus Disease (COVID-19)
-
Media ReleaseAveXis Community Statement on the Global Managed Access Program for AVXS-101
-
Media ReleaseNovartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention
-
Media ReleaseNovartis receives complete response letter from U.S. FDA for inclisiran
-
Media ReleaseNovartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis
-
Media ReleaseNovartis Entresto® granted expanded indication in chronic heart failure by FDA
-
Media ReleaseNovartis Cosentyx® gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis
-
Media ReleaseNovartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)
-
Media ReleaseNovartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
-
Media ReleaseNovartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- › Next page